Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Assessment of anti-adeno-associated virus (AAV) antibodies in patients prior to systemic gene therapy administration is an important consideration regarding efficacy and safety of the therapy. Approximately 30%-60% of individuals have pre-existing anti-AAV antibodies. Seroprevalence is impacted by multiple factors, including geography, age, capsid serotype, and assay type. Anti-AAV antibody assays typically measure (1) transduction inhibition by detecting the neutralizing capacity of antibodies and non-antibody neutralizing factors, or (2) total anti-capsid binding antibodies, regardless of neutralizing activity. Presently, there is a paucity of head-to-head data and standardized approaches associating assay results with clinical outcomes. In addition, establishing clinically relevant screening titer cutoffs is complex. Thus, meaningful comparisons across assays are nearly impossible. Although complex, establishing screening assays in routine clinical practice to identify patients with antibody levels that may impact favorable treatment outcomes is achievable for both transduction inhibition and total antibody assays. Formal regulatory approval of such assays as companion diagnostic tests will confirm their suitability for specific recombinant AAV gene therapies. This review covers current approaches to measure anti-AAV antibodies in patient plasma or serum, their potential impact on therapeutic safety and efficacy, and investigative strategies to mitigate the effects of pre-existing anti-AAV antibodies in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“…May be effective in the presence of low-titer (1:5 – 1:17) NAbs 93,96 (cid:1) The higher vector load could trigger an anti-capsid T cell response 96,136 , which is a potential safety risk, particularly in the setting of pre-existing humoral response Example: Tenfold increase in vector dose…”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 2×
“8 AAV sero-types differ in their tissue tropism 10,11 ; therefore, the selection of an appropriate AAV serotype further enables targeted tissue expression.”
BackgroundIgG placental transfer in healthy and pathological pregnancies
Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A., & Carneiro-Sampaio, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/985646 · Cited by 1,037
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 3×
“GTx-related approaches include using higher GTx doses, 72,116,117 co-administering empty “ decoy ” capsids, 72,97,115,116 local delivery to the target organ or tissue, 43,47,115,116,118 use of alternate capsids, or cloaking the rAAV capsid.”
BackgroundMethodOverview of complement activation and regulation
Noris, M., & Remuzzi, G. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.001 · Cited by 864
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377
IgG endopeptidase in highly sensitized patients undergoing transplantation
Jordan, S. C., Lorant, T., Choi, J., Kjellman, C., Winstedt, L., Bengtsson, M., Zhang, X., Eich, T., Toyoda, M., Eriksson, B.-M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612567 · Cited by 377
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358 · cited 4×
“13 These antibodies can potentially inhibit the transduction of target cells by rAAV vectors, thus impeding successful gene transfer, and may have potential safety consequences.”
BackgroundInfluentialOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355 · cited 2×
“Moreover,mutatedcapsidswerereportedtoadsorbantibodieswithoutenteringthetargetcell 117 Modify capsid/switch AAV serotype or engineering/ cloaking of AAV: reduce capsidsusceptibilitytoNAbs Coupled immunomodulation via cloaking is technically feasible, although such a strategy remains challenging in…”
BackgroundMethodAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · cited 4×
“93 In contrast, a study investigating the effect of AAV9 Abs on transduction ef fi ciency in macaques reported that anti-AAV9 TAb titers up to 1:400 did not block hepatic gene transfer.”
BackgroundInfluentialScallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254
Humoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243 · cited 8×
“Detailed reports of assay (cid:1) Minimizes systemic exposure to the vector 43,47,115,116,118 (cid:1) This option is not suitable for all target tissues, and some administration routes may elicit strong T cell responses against the transgene 115 (cid:1) Example: Subretinal delivery of AAV2-hRPE65v2…”
BackgroundMethodInfluentialEngineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215 · cited 3×
“…via cloaking is technically feasible, although such a strategy remains challenging in terms of engineering and manufacturing the capsid 115,119 Engineering capsid could deleteriously modify tissue tropism and increase cross-reactivity among AAV serotypes 47,116,138…”
BackgroundWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212 · cited 1×
“Previous rAAV GTx studies in animals 27,93 – 95 and humans 96 – 99 demonstrated that pre-existing anti-AAV NAbs can limit or completely block transgene expression even at low titers.”
BackgroundChand, D. H., Zaidman, C., Arya, K., Millner, R., Farrar, M. A., Mackie, F. E., Goedeker, N. L., Dharnidharka, V. R., Dandamudi, R., & Reyna, S. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.11.054 · Cited by 210 · cited 1×
“112,113 Not all clinical trials have used AAV seropositivity as an exclusion criterion.”
BackgroundMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206 · cited 7×
“…are designed to suppress the humoral immune response by reducing antibody production (for example, by using immunosuppressive drugs), 16,47,97,116,120,121 or by reducing the levels of serum IgG by plasmapheresis, 47,115,116,122,123 preconditioning with IgG-degrading enzyme of certain…”
BackgroundMethodInfluentialMonteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · cited 3×
“…(for example, by using immunosuppressive drugs), 16,47,97,116,120,121 or by reducing the levels of serum IgG by plasmapheresis, 47,115,116,122,123 preconditioning with IgG-degrading enzyme of certain Streptococcus species (IdeS or IdeZ), 124,125, and neonatal crystallizable fragment receptor…”
BackgroundInfluentialPien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
Kruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F. M., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.014 · Cited by 182
Adeno-Associated Virus Integration: Virus versus Vector
Smith, R. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.55 · Cited by 178
Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors
Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., & Muruve, D. A. (2008) · Journal of Virology · doi:10.1128/jvi.01990-07 · Cited by 177
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174 · cited 1×
“…the capsid 115,119 Engineering capsid could deleteriously modify tissue tropism and increase cross-reactivity among AAV serotypes 47,116,138…”
BackgroundAddressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Kishimoto, T. K., & Samulski, R. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2060737 · Cited by 152
Amado, D., Mingozzi, F., Hui, D., Bennicelli, J. L., Wei, Z., Chen, Y., Bote, E., Grant, R. L., Golden, J. A., Narfstrom, K., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000659 · Cited by 140
Mingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Elmore, Z. C., Oh, D. K., Simon, K. E., Fanous, M. M., & Asokan, A. (2020) · JCI Insight · doi:10.1172/jci.insight.139881 · Cited by 137
The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Majowicz, A., Nijmeijer, B., Lampen, M. H., Spronck, L., de Haan, M., Petry, H., van Deventer, S. J., Meyer, C., Tangelder, M., & Ferreira, V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.009 · Cited by 126
Mendell, J. R., Connolly, A. M., Lehman, K. J., Griffin, D. A., Khan, S. Z., Dharia, S. D., Quintana-Gallardo, L., & Rodino-Klapac, L. R. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.011 · Cited by 124 · cited 1×
“23,24 As TAb assays only detect antibodies, 48 they do not measure non-antibody neutralizing factors.”
BackgroundKlamroth, R., Hayes, G., Andreeva, T., Gregg, K., Suzuki, T., Mitha, I. H., Hardesty, B., Shima, M., Pollock, T., Slev, P., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.287 · Cited by 118
Mingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112 · cited 1×
“13,45 Substantial cross-reactivity of anti-AAV antibodies between the serotypes is evident, 46 which is most likely explained by the high degree of AAV capsid sequence homology.”
BackgroundStrategy to detect pre-existing immunity to AAV gene therapy
Falese, L., Sandza, K., Yates, B., Triffault, S., Gangar, S., Long, B., Tsuruda, L., Carter, B., Vettermann, C., Zoog, S. J., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.95 · Cited by 101
Veron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200620 · Cited by 88
Smith, C. J., Ross, N., Kamal, A., Kim, K. Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W. J., Singh, I., Majowicz, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999021 · Cited by 86 · cited 1×
“112,113 Not all clinical trials have used AAV seropositivity as an exclusion criterion.”
BackgroundAge-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort
Perocheau, D. P., Cunningham, S. C., Lee, J., Antinao Diaz, J., Waddington, S. N., Gilmour, K., Eaglestone, S., Lisowski, L., Thrasher, A. J., Alexander, I. E., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.098 · Cited by 81
Strategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
Hemophilia gene therapy comes of age
George, L. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.587 · Cited by 58
Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays
Gorovits, B., Fiscella, M., Havert, M., Koren, E., Long, B., Milton, M., & Purushothama, S. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0403-1 · Cited by 57 · cited 9×
“49 The neutralizing titer is usually de fi ned as the highest serum dilution that reduces rAAV transgene expression by a speci fi ed amount (e.g., R 50”
BackgroundMethodInfluentialGorovits, B., Azadeh, M., Buchlis, G., Harrison, T., Havert, M., Jawa, V., Long, B., McNally, J., Milton, M., Nelson, R., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00628-3 · Cited by 53
Fu, H., Meadows, A. S., Pineda, R. J., Kunkler, K. L., Truxal, K. V., McBride, K. L., Flanigan, K. M., & McCarty, D. M. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.109 · Cited by 44
Gardner, M. R., Mendes, D. E., Muniz, C. P., Martinez-Navio, J. M., Fuchs, S. P., Gao, G., & Desrosiers, R. C. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.003 · Cited by 30 · cited 1×
“78 However, a study involving healthy volunteers using both TAb and TI assays for AAV5 found that a subset of individuals was positive in one assay and negative in the other.”
Background
Cited by
Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173510 · Cited by 159
“Complement activation by AAV is primarily antibody dependent (classical pathway), triggered by anti-capsid IgM and IgG antibodies that can cause complement-mediated cell damage (18).”
BackgroundInfluentialSelf-citationImmune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
Rana, J., Herzog, R. W., Muñoz-Melero, M., Yamada, K., Kumar, S. R. P., Lam, A. K., Markusic, D. M., Duan, D., Terhorst, C., Byrne, B. J., et al. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101216 · Cited by 26
Self-citation
Metadata
- Authors
- Schulz, M., Levy, D. I., Petropoulos, C. J., Bashirians, G., Winburn, I., Mahn, M., Somanathan, S., Cheng, S. H., & Byrne, B. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 31
- Issue
- 3
- Pages
- 616-630
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W4315643308
- Cited by
- 125
- References
- 51
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.